Long-time Mela Sciences (NSDQ:MELA) CEO Joseph Gulfo resigned last week from his position as chief executive, president, chairman and member of the board. Gulfo had been Mela’s CEO since 2004, and company documents did not cite a reason for his resignation.
Histogenics has a new face in the corner office with the appointment of Peter Greenleaf, an AstraZeneca veteran favored by the board for his experience moving products toward commercialization.
The company has its eyes on an end-stage pivotal trial for NeoCart, a device that uses patients’ own cells to regenerate knee cartilage.
The Indian government slashed reimbursement rates for drug-eluting stents by more than 61.5%, down to about $460 from roughly $1,200, aiming to give a boost to its domestic stents industry at the expense of the multinational players.
It’s the 2nd rate cut since October 2011, according to the Business Standard. India cut the rate of reimbursement for U.S.-made stents from 65,000 rupees (about $1,200) to 25,000 rupees (~$461), which is now the standard rate for stents regardless of origin, according to the newspaper.
New Minnetronix CFO started yesterday
The new CFO of Minnetronix, Phil Ankeny, joined the company today. Ankeny moved over to Minnetronix from SurModics Inc., where he served as interim CEO and CFO. His background is in venture capital, IT startups and investment banking.
The San Carlos, Calif.-based diagnostic and device maker posted a $4.76 million, or 29¢ per diluted share profit, on sales of $90.5 million during the 3-month period on December 31st, compared with a $17.3 million, or 14¢ per diluted share loss, on sales of $64.1 million during the same period last year.
Ivantis said it raised a $27 million Series B round led by Ascension Health Ventures aimed at funding a quartet of clinical trials for its Hydrus Microstent glaucoma treatment.
The Irvine, Calif.-based medical device company said the device, an eyelash-sized stent, is designed to reduce eye pressure.
HOLX shares reached their highest level since May 2011 yesterday, peaking at $23.22 apiece before closing at $22.36, up 7.0% on the day. Shares were trading at $22.39 as of about 12:50 p.m. today.